BBT-877
- Generic Name
- BBT-877
- Drug Type
- Small Molecule
- Background
BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
Brainomix and Medtronic Form Strategic Alliance to Transform Stroke Care with AI Technology
• Brainomix and Medtronic Neurovascular have partnered to integrate AI-powered imaging solutions across Western Europe, aiming to enhance stroke diagnosis and treatment delivery.
• The Brainomix 360 Stroke platform has demonstrated significant impact in real-world studies, doubling thrombectomy rates and showing a 37% increase in treatment compared to non-evaluation sites.
• The collaboration combines Brainomix's AI imaging expertise with Medtronic's neurovascular technology leadership to accelerate treatment decisions and improve patient outcomes across the region.
Bridge Biotherapeutics Partners with Brainomix to Leverage AI in Lung Fibrosis Trial
Bridge Biotherapeutics collaborates with Brainomix to utilize AI-powered e-ILD software in a phase 2 trial for idiopathic pulmonary fibrosis (IPF) treatment, BBT-877. This partnership aims to enhance the assessment of therapeutic efficacy through advanced imaging analysis, potentially offering early insights into treatment response and disease progression.
Novel Therapies Show Promise in Idiopathic Pulmonary Fibrosis Treatment
• Bridge Biotherapeutics' BBT-877, a first-in-class autotaxin inhibitor, is undergoing Phase 2 trials with data expected in April, showing promising safety and efficacy.
• Daewoong Pharmaceutical's Versiporocin (DWN12088), targeting PRS protein action, is in Phase 2 trials and has received FDA and EMA rare drug designations, aiming for completion in 2025.
• Ildong Pharmaceutical is developing IL1512, a CXCR7-selective agent, set to enter GLP toxicity testing, while Hanmi Pharmaceutical's HM15211 shows promise in preclinical studies for IPF.
• The IPF treatment market is projected to grow from $4.6 billion to $7 billion by 2030, driven by unmet needs and the pursuit of first-in-class and best-in-class therapies.
Boehringer Ingelheim Seeks Approval for Nerandomilast After Positive Phase III IPF Trial
• Boehringer Ingelheim is seeking regulatory approval for nerandomilast after its Phase III FIBRONEER-IPF trial met the primary endpoint of improving forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF).
• The FIBRONEER-IPF trial, involving 1,177 patients, demonstrated that nerandomilast significantly improved lung function compared to placebo over 52 weeks; full data will be presented in H1 2025.
• Nerandomilast, a preferential phosphodiesterase 4B (PDE4B) inhibitor, received breakthrough therapy designation from the FDA in 2022 and is also being investigated for progressive fibrosing interstitial lung diseases.
• With limited FDA-approved treatments for IPF, nerandomilast represents a potential new option, as the trial is the first successful late-stage IPF trial in a decade.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath